Business · 01/07/2022Updated: 10/17/2026 · 1 min read
FDA Determines Regulatory Review Period for IMCIVREE Patent Extension
Summary
The US Food and Drug Administration has officially confirmed the review period for IMCIVREE, a human drug product, in accordance with patent extension regulations, following a submission to the US Patent and Trademark Office.
Original source language: Federal Register — Food and Drug AdministrationOpen original release →